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Drug-induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy
may contribute to diagnostic accuracy, but the histological features of DILI and their relation-
ship to biochemical parameters and outcomes are not well defined. We have classified the
pathological pattern of liver injury and systematically evaluated histological changes in liver
biopsies obtained from 249 patients with suspected DILI enrolled in the prospective, observa-
tional study conducted by the Drug Induced Liver Injury Network. Histological features were
analyzed for their frequency within different clinical phenotypes of liver injury and to identify
associations between clinical and laboratory findings and histological features. The most com-
mon histological patterns were acute (21%) and chronic hepatitis (14%), acute (9%) and
chronic cholestasis (10%), and cholestatic hepatitis (29%). Liver histology from 128 patients
presenting with hepatocellular injury had more severe inflammation, necrosis, and apoptosis
and more frequently demonstrated lobular disarray, rosette formation, and hemorrhage than
those with cholestasis. Conversely, histology of the 73 patients with cholestatic injury more
often demonstrated bile plugs and duct paucity. Severe or fatal hepatic injury in 46 patients
was associated with higher degrees of necrosis, fibrosis stage, microvesicular steatosis, and
ductular reaction among other findings, whereas eosinophils and granulomas were found
more often in those with milder injury. Conclusion: We describe an approach for evaluating
liver histology in DILI and demonstrate numerous associations between pathological findings
and clinical presentations that may serve as a foundation for future studies correlating DILI
pathology with its causality and outcome. (HEPATOLOGY 2014;59:661-670)
D
rug-induced liver injury (DILI) is an impor-
tant cause of liver disease with significant
morbidity and mortality.1,2 Accurate and early
diagnosis is important, but challenging.3,4 There are
no specific markers or diagnostic tests for DILI, and
the diagnosis is by exclusion.5 In many instances, liver
histology is considered helpful in strengthening the
diagnosis or excluding other potential causes of liver
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injury. A key aspect of this evaluation is careful classifi-
cation of the pattern of injury and a detailed description
of the histological findings,6,7 yet there are limited
examples of the application of this method across the
spectrum of histological injury found in DILI. The
Drug-Induced Liver Injury Network (DILIN) is an
ongoing, multicenter observational study of consecutive
cases of DILI enrolled at eight geographically distributed
academic medical centers in the United States.8 The
central aims of the DILIN are to more fully characterize
the clinical syndromes of liver injury caused by prescrip-
tion and nonprescription medications, and herbals and
dietary supplements (HDS), standardize terminology
and grading systems, and provide resources for mecha-
nistic studies of DILI. For these purposes, carefully
accrued clinical cases of suspected DILI are enrolled and
followed longitudinally. Each case is reviewed by a cau-
sality committee using a formal adjudication process.9
In this study, liver biopsies taken at the time of pre-
sentation as part of a diagnostic assessment provided
an opportunity to systematically assess the patterns of
injury across this diverse patient population. In this
article, we present this standardized method of evalua-
tion and classification of histological features and
demonstrate the most frequent associations among his-
tological findings, laboratory data, clinical phenotype,
and injury severity at presentation.
Patients and Methods
Patients with suspected DILI were enrolled in the
DILIN Prospective Study, and data were collected as
previously described.5 Patients or their next of kin pro-
vided written informed consent, which included
pathology review. If available, up to 10 unstained
recuts of liver tissue (needle or wedge biopsies,
explanted native livers, and autopsies) obtained at
investigator discretion were sent to the central pathol-
ogy core laboratory (National Cancer Institute,
Bethesda, MD) for repeat staining and storage. Slides
were stained with hematoxylin and eosin, Masson’s
trichrome, reticulin, iron, copper, and periodic acid-
Schiff with diastase. Biopsies were reviewed by the
central hepatic pathologist (D.E.K.), who was blinded
to all clinical information including the name(s) of the
implicated drugs. All liver tissues received the same prede-
fined structured histological evaluation. This systematic
evaluation of 48 separate histologic features was divided
into seven broad categories: inflammation; necrosis/cell
injury; fibrosis; steatosis; cholestasis; vascular injury; and
other findings, including evaluation of special stains (Sup-
porting Table 1).10 The number of portal areas (complete
and partial) was recorded as a measure of biopsy ade-
quacy. The diagnostic classification used (Supporting
Table 2) was based on published descriptions of patho-
logic changes in DILI.11,12 Standard hepatopathological
diagnostic criteria13 were used to define patterns of injury.
Overall injury pattern was classified into 1 of 18 patterns:
acute hepatitis; chronic hepatitis; acute cholestasis;
chronic cholestasis; cholestatic hepatitis (mixed hepatocel-
lular and cholestatic injury); granulomatous changes; stea-
tosis (macrovesicular or microvesicular); steatohepatitis;
coagulative/confluent necrosis (zonal or nonzonal); mas-
sive/submassive necrosis; vascular injury; hepatocellular
alteration; nodular regenerative hyperplasia; mixed or
otherwise unclassifiable injury; minimal nonspecific
changes, and absolutely normal.
For the purposes of the current analysis, a biopsy
was eligible for inclusion if it was obtained within 6
months of the protocol-defined DILI onset date and
was adequate, in the pathologist’s opinion, to assign a
pattern of injury. Tissues from explants or autopsies
were excluded. If two biopsies qualified from the same
patient, the larger biopsy was used. Once the biopsy
data from blinded review were recorded, additional
information was abstracted from the DILIN prospec-
tive database, including patient age, sex, and laboratory
data (alanine aminotransferase [ALT], alkaline phos-
phatase [ALP], and total bilirubin) at the time of DILI
onset and at or around the time of liver biopsy (within
7 days). The biochemical injury pattern (hepatocellu-
lar, mixed, or cholestatic) was calculated as the ratio
(R) of ALT to ALP normalized by their respective
upper limits of normal (ULN) from laboratory data at
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the time of onset. If a suspected case had undergone
causality determination,9 then the causality score,
severity score, and implicated medications were also
obtained from the database.
Statistical Analysis. Chi-square and Fisher’s exact
tests were used to compare nominal variables. Mann-
Whitney’s U test was used to evaluate continuous vari-
ables stratified by a nominal variable.
Results
Description of Population. From September 2004
through October 2010, 249 patients with suspected
DILI underwent a liver biopsy that was made available,
reviewed centrally, and entered into the DILIN Prospec-
tive Study database (Table 1). Mean age of patients in
this cohort was 48 years (range, 7-87), and 144 (58%)
were female. Biopsies contained a mean of 16.6 portal
areas (median, 13) and generally were adequate to per-
form histological evaluations. Mean time from DILI
onset to liver biopsy was 25 days (median, 14; inter-
quartile range: 29). Causality evaluation was completed
on 212 (84%) cases, with a final assessment of definite,
highly likely, or probable in 174 (70%).9 Of these
cases, 117 (67%) had a single agent implicated, whereas
the rest had multiple implicated drugs or HDS prod-
ucts. Comparison of histological findings between cases
adjudicated as probable to definite and those adjudi-
cated as unlikely or possible showed few differences.
Biopsies from the probable to definite group were more
likely to have increased eosinophils (45% vs. 26%;
P5 0.04), less likely to show ductular reaction (33%
vs. 53%; P5 0.04), and had less hepatocellular iron
accumulation (P5 0.0008).
Frequency of individual histological findings is shown
in Table 2 and Supporting Table 3. Inflammation and
cholestasis were common. Interface hepatitis was noted
in 91%, spotty lobular inflammation was noted in
99%, and some degree of cholestasis in 50%. Apoptosis
and confluent necrosis were also frequently noted, with
apoptotic bodies in 77% and areas of confluent necrosis
in 25% of cases. Although almost all of the predefined
characteristics were used, no case showed ductal choles-
tasis or peliosis. No cases were classified as having mac-
rovesicular steatosis or nonzonal necrosis as the
dominant pathology pattern of injury, although both
were noted as components of other patterns of injury.
The most common patterns of injury were those
defined by primary features of either inflammation or
cholestasis or both—the first five diagnostic patterns of
injury, acute and chronic hepatitis, acute and chronic
cholestasis, and cholestatic hepatitis, were used to classify
83% of cases (Figs. 1A and 2). Variation in common his-
tological features among the different general patterns of
injury is shown in Table 3. Cases that were characterized
as acute hepatitis had the most severe inflammation and
were more likely to have confluent necrosis and apopto-
sis. In contrast, acute cholestatic cases showed the mildest
degree of these features. Among the three cholestatic pat-
terns, cholestatic hepatitis cases had a similar degree of
bile stasis as the acute cholestatic cases, but more inflam-
mation and hepatocellular injury, representing an overlap
between the two distinct histologic patterns. Chronic
cholestatic cases were more likely to have duct injury,
duct paucity, cholate stasis, and copper accumulation. A
mild degree of fibrosis was present in many cases, but
most pronounced in those that were classified as chronic
hepatitis. Table 3 also shows patterns of injury observed
for selected agents where only a single agent was identi-
fied as the cause of the injury.
Relationship of Findings to Biochemical Injury
Classification. Suspected DILI was classified based
upon the value of the ratio (R) of ALT to ALP levels
(expressed as multiples of the ULN) obtained at the
onset of injury.14 Hepatocellular injury was defined as
an R ratio >5, cholestatic injury an R <2, and
“mixed” cholestatic-hepatocellular injury as an R ratio
between 2 and 5. This terminology was used regardless
of the presence of jaundice. The ability of the R ratio
Table 1. Characteristics of 249 Patients With Suspected
DILI Undergoing Biopsy
N (%)
Female 144 (57.8)
Age, mean (range) 48 (7-87)
Agents implicated
Single agent 172 (69.1)
Two agents 56 (22.5)
Three agents 21 (8.4)
Most common agents implicated
Amoxicillin/clavulanate 19 (7.6)
Nitrofurantoin 11 (4.4)
Sulfamethoxazole/trimethoprim 9 (3.6)
Minocycline 8 (3.2)
Ciprofloxacin 7 (2.8)
Anabolic agents 6 (2.4)
Azithromycin 5 (2)
Levofloxacin 5 (2)
Causality process completed 208 (83.5)
Definite 53 (21.3)
Very likely 84 (33.7)
Probable 33 (13.3)
Possible 24 (9.6)
Unlikely 14 (5.6)
DILIN severity score
Mild 40 (16.1)
Moderate 39 (15.7)
Moderate-hospitalized 83 (33.3)
Severe 31 (12.5)
Fatal/transplanted 15 (6.0)
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to predict histological findings and patterns of injury
has not been rigorously analyzed. Distribution of his-
tological findings stratified by R ratios calculated from
initial laboratory results are shown in Fig. 1 and Table
2. Many correlations were evident. Patients with hepa-
tocellular injury tended to have more inflammation,
more necrosis, and more apoptosis. Inflammation was
assessed using the Ishak scale,15 because of its familiar-
ity, and all four subscales (interface hepatitis, lobular
inflammation, portal inflammation, and confluent
necrosis) showed higher scores in hepatocellular injury
cases. Plasma cells and eosinophils were usually located
in portal areas and were more often increased in hepa-
tocellular injury. When present, confluent necrosis usu-
ally involved zone 3, with more severe manifestations
showing bridging or multiacinar necrosis. Other
changes associated with hepatocellular injury included
hepatocyte rosette formation, lobular disarray, and
hemorrhage, all features observed in cases of severe
parenchymal injury. In contrast, patients with choles-
tatic biochemical injury tended to have canalicular
and hepatocellular cholestasis in zone 3 and the
degree of cholestasis was more severe. Ductal paucity,
portal venopathy, sinusoidal dilation, and nodular
regenerative hyperplastic changes were also more
common in cholestatic injury. Distribution of histo-
logical changes in mixed injury was more similar to
that of cholestatic than hepatocellular injury. With
respect to injury pattern, patients with hepatocellular
injury were more likely to have acute or chronic hep-
atitic changes on biopsy and less likely to have acute
or chronic cholestasis. Cases of cholestatic hepatitis
were nearly evenly distributed between hepatocellular,
mixed, and cholestatic injury, reflecting the wide vari-
ation in the degree of hepatitis and cholestasis in this
category.
The range of R ratios at the onset of injury for
selected histologic patterns is displayed in Fig. 1B.
Table 2. Distribution of Selected Histological Findings According to Biochemical Classification at Onset of Suspected DILI
Biochemical Presentation
Feature All Cases Hepatocellular Mixed Cholestatic P Value
N 249 128 48 73
Interface hepatitis, mean 2.21 2.63 2.17 1.5 <0.0001
Lobular inflammation, mean 3.00 3.29 2.81 2.62 <0.0001
Portal inflammation, mean 1.66 1.87 1.58 1.36 0.0080
Confluent necrosis, mean 1.11 1.71 0.67 0.36 0.0003
Plasma cells 56 (23) 40 (32) 7 (15) 9 (12) 0.0020
Eosinophils 94 (38) 60 (48) 17 (35) 17 (23) 0.0030
Lipogranulomas 47 (19) 16 (13) 16 (33) 15 (21) 0.0080
Apoptosis
None 56 (23) 15 (12) 15 (31) 26 (36) <0.0001
<1 per 403 HPF 121 (49) 52 (41) 26 (54) 43 (59)
1-3 per 403 HPF 57 (23) 47 (37) 6 (13) 4 (5)
>3 per 403 HPF 13 (5) 12 (10) 1 (2) 0 (0)
Degree of necrosis
None 186 (75) 83 (65) 41 (87) 62 (85) 0.0070
<5% 23 (9) 14 (11) 1 (2) 8 (11)
5%-33% 20 (8) 16 (13) 1 (2) 3 (4)
33%-67% 13 (5) 10 (8) 3 (6) 0 (0)
>67% 5 (2) 4 (3) 1 (2) 0 (0)
Hepatocyte rosettes 76 (31) 57 (45) 8 (17) 11 (15) <0.0001
Lobular disarray 46 (19) 42 (33) 2 (4) 2 (3) <0.0001
Fibrosis stage, mean 1.31 1.38 1.40 1.24 0.3500
Cholestasis grade, mean 1.71 0.68 1.08 1.53 <0.0001
Hepatocellular cholestasis 112 (45) 41 (32) 23 (48) 48 (66) <0.0001
Canalicular cholestasis 120 (48) 50 (39) 23 (48) 47 (64) 0.0030
Ductal paucity
None 231 (95) 123 (98) 45 (96) 63 (89) 0.0200
Mild 7 (3) 0 (0) 1 (2) 6 (8)
Moderate to marked 6 (2) 3 (2) 1 (2) 2 (3)
Portal venopathy 10 (4) 1 (1) 2 (5) 7 (10) 0.0080
Hemorrhage 25 (10) 21 (17) 2 (4) 2 (3) 0.0030
Sinusoidal dilation (moderate to marked) 12 (5) 5 (4) 0 (0) 7 (10) 0.0400
Nodular transformation 10 (4) 2 (2) 0 (0) 8 (11.6) 0.0010
Data are shown as N (%) or as mean values. Means of scores are shown only for simplicity. Chi-square analysis was used to determine significance of variation
across the three biochemical presentations.
Abbreviation: HPF, high power field.
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Although the range varied between these pathologic
patterns of injury, there was also significant overlap.
Relationship of Histology to Laboratory Data at
the Time of Biopsy. To better understand the rela-
tionship of histological findings to common serum
biochemical markers, we compared the histological
findings to laboratory data obtained at, or close to, the
time of liver biopsy, limiting the comparison to bio-
chemical data collected within 7 days of biopsy. To
simplify the analysis, laboratory data were dichotom-
ized, using 5 times the ULN as the breakpoint for
ALT, 3 times the ULN for ALP, and 3 mg/dL for total
bilirubin. The significant associations are shown in
Supporting Table 4; associations with P> 0.05 are not
shown. Histological features associated with ALT levels
>5 times the ULN were similar to those associated
with hepatocellular injury. Elevated ALP was associated
with some, but not all, of the cholestatic changes. Spe-
cifically, the degree of cholestasis was worse and there
were more cases of cholate stasis, duct injury, and duct
paucity. Almost all (38 of 40) of the cases in which
microvesicular steatosis was observed had low ALP lev-
els as did all of the cases with hepatocellular inclu-
sions, which were mostly megamitochondria. Changes
of inflammation and necrosis were not associated with
ALP levels.
In Table 4, these biochemical-histological associa-
tions were compared with the similar associations
described by Hyman Zimmerman in his classic text-
book on DILI,11 which were based upon his clinical
experience reviewing large numbers of cases both clini-
cally and histologically. There was good correspon-
dence, although, for acute hepatitis and zonal necrosis,
our range of ALT did not extend as high, probably
because the DILIN’s exclusion of patients with acet-
aminophen injury and relatively few patients with
acute liver failure.
Relationship of Histological Findings to Clinical
Severity. Each case in the DILIN prospective study
was assigned a score ranging from 1 to 5 for clinical
severity level based on clinical and laboratory find-
ings.1 Mild cases (11) were defined as serum enzyme
elevations without jaundice (total bilirubin <2.5 mg/
dL); moderate cases (21) had jaundice (total bilirubin
>2.5 mg/dL) and were not hospitalized for the liver
injury; moderately severe cases (31) had jaundice and
were hospitalized; severe cases (41) had jaundice and
evidence of hepatic failure (any combination of pro-
longation of international normalized ratio, ascites, or
encephalopathy) or other organ failure (renal, bone
marrow, or lung); and fatal cases (51) were those who
died as a result of hepatic failure or underwent liver
transplantation (LT) within 6 months of onset. Associ-
ations between severity scores and histological features
are shown in Table 5. Degree of necrosis, fibrosis
stage, microvesicular steatosis, panacinar steatosis, chol-
angiolar cholestasis, ductular reaction, neutrophils, and
portal venopathy were all associated with higher scores
of severity (Fig. 3A-C). Granulomas and eosinophils
were more likely to be noted in milder cases (Fig.
3D). Fatal outcome was more likely in patients with
an injury pattern of zonal necrosis (13% vs. 3%) or
with mixed injury (27% vs. 3%; P5 0.019).
Discussion
We and others6,7 have argued that when pathologists
review and report on DILI, they should classify the
Fig. 1. Relationship between pathological injury patterns and bio-
chemical presentation. (A) The association of particular patterns with
biochemical presentation was significant by chi-square analysis. (B)
box plot showing range of “R” for selected histological patterns of
injury. “R” is defined as the normalized ratio of ALT to ALP. The number
of cases of each pattern of injury is shown above each box plot. Red
dotted lines indicate the dividing point between hepatocellular (R >
5), mixed (R5 2-5), and cholestatic (R < 2) reactions.
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changes as a particular pattern of pathological injury.
Pattern classification is critical to define the pathologi-
cal differential diagnosis, which can be used in con-
junction with the clinical evaluation to establish the
etiology of the injury. For the purposes of DILIN, we
predefined 18 histological patterns that were likely to
be encountered given the kinds of patients and drug
etiologies that we expected to accrue. We did not
include tumors in the classification, despite well-
described associations between drugs and tumors.
Although the clinical cases of DILI in this cohort had
a great diversity of findings, nearly 83% of our 249
cases could be classified into one of five patterns: acute
hepatitis; chronic hepatitis; acute cholestasis; chronic
cholestasis; and cholestatic hepatitis. This distribution
reflects both the character of our patient population
and the injury patterns associated with the most
commonly implicated drugs, particularly antibiotics,
psychoactive agents, and drugs used to treat musculo-
skeletal disorders.5 Other populations with different
types of drug injury may display different frequencies
of the various injury patterns, and so we would recom-
mend that pathologists use the full spectrum of possi-
ble patterns when reporting on DILI. Despite the
variety of injury patterns observed, there was good cor-
relation between biochemical tests at the time of
Fig. 2. Examples of the five most common injury patterns. (A) Acute hepatitic injury resulting from ciprofloxacin. (B) Chronic hepatitic injury
resulting from isoniazid. (C) Acute cholestatic injury resulting from an anabolic steroid. (D) Chronic cholestatic injury resulting from amoxicillin-
clavulanate (inset shows positive copper stain). (E and F) Cholestatic hepatitic injury resulting from duloxetine. For orientation, P indicates portal
area, V indicates central vein, and arrows indicate canalicular cholestasis.
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biopsy and individual histological findings. These asso-
ciations serve to validate the use of systematic histolog-
ical scoring methods across the range of pathology that
is observed in suspected DILI.
One of the standard definitions used in the study of
DILI is the division of cases cholestatic, mixed, and
hepatocellular injury using results of commonly used
biochemical tests, based upon the normalized ratio of
ALT to ALP, sometimes referred to as the “R” value.
These definitions are used based upon the R ratio
determined at or near the time of presentation,
although the ratio may change markedly over time as
enzyme levels rise and fall. The current analysis
showed that there was a limited correlation between
the biochemical categorization and the pathological
pattern of injury. For example, a patient with hepato-
cellular injury might show any of a number of histo-
logical patterns on biopsy, including acute cholestasis.
Likewise, an injury that would be classified as choles-
tatic on biochemical grounds could show acute or
chronic hepatitis without any evidence of bile accumu-
lation. It is possible that other methods of classifying
biochemical injury, such as examining the profile over
time or including changes in bilirubin levels would
provide clearer correlation with histological findings,
but, for now, it is clear that it is inappropriate to draw
conclusions about the precise nature of histological
findings based solely on the biochemical classification
determined at or near the time of onset of injury.
Another area of interest is the potential relationship
between specific histological features and clinical sever-
ity of liver injury. Studies of acute liver failure have
demonstrated that both the degree of necrosis and the
presence of ductular reaction on liver biopsy correlate
with eventual LT and death.16 Although our patient
population included many patients who did not have
liver failure, extensive necrosis and ductular reaction
Table 4. Range of ALT and ALP by Injury Pattern
Labs at Biopsy Zimmermany
Injury Pattern ALT/ULN* (3) ALP/ULN* (3) ALT/ULN (3) ALP/ULN (3)
Acute hepatitic 12.8-27.4 1.0-2.9 10-100 1-3
Chronic hepatitic 3.4-9.5 0.9-2.3 3-50 1-3
Acute cholestatic 2.1-10.0 1.3-3.8 1-5 1-3
Chronic cholestatic 2.5-11.5 2.2-8.4 1-5 3-20
Cholestatic hepatitic 1.7-13.1 1.2-3.2 1-10 >3
Necrosis (zonal) 6.4-46.7 0.9-1.7 10-1,000 1-3
*Ranges represent 25th to 75th percentile of the laboratory data obtained
at the time of liver biopsy, with ALT and ALP normalized to the local laboratory
ULN.
Ranges adapted from Tables 4.25 and 4.26 on p. 103 of a previous work.9
Table 3. Variation in Selected Histopathologic Features Between the Most Common Injury Patterns
Acute Hepatitic Chronic Hepatitic Acute Cholestatic Chronic Cholestatic Cholestatic Hepatitic
N 51 35 23 25 74
Feature
Interface hepatitis, mean 3.14 2.69 0.61 1.88 2.22
Lobular inflammation, mean 3.73 3.00 1.65 2.48 3.38
Portal inflammation, mean 2.14 2.14 0.74 1.52 1.60
Confluent necrosis, mean 2.08 1.17 0.09 0.36 1.00
Plasma cells 18 (35) 13 (37) 0 (0) 3 (12) 18 (25)
Neutrophils 16 (31) 2 (6) 3 (13) 6 (24) 31 (43)
Lymphoid aggregates or germinal centers 7 (14) 11 (31) 0 (0) 2 (8) 5 (7)
Apoptosis 1.78 1.0 0.61 0.80 1.07
Degree of necrosis, mean 0.84 0.37 0.05 0.12 0.38
Hepatocyte rosettes 27 (54) 12 (34) 0 (0) 5 (20) 23 (32)
Lobular disarray 29 (58) 1 (3) 0 (0) 0 (0) 16 (22)
Fibrosis stage, mean 0.94 2.31 0.59 1.52 1.11
Grade of cholestasis, mean 0.04 0 2.09 0.84 2.07
Hepatocellular cholestasis 0 (0) 0 (0) 22 (96) 8 (32) 68 (92)
Canalicular cholestasis 3 (6) 0 (0) 21 (91) 8 (32) 74 (100)
Cholate-stasis 4 (8) 2 (6) 4 (17) 23 (92) 22 (30)
Duct injury, multiple ducts 20 (40) 8 (24) 6 (27) 18 (78) 38 (52)
Ductal paucity, mild or worse 0 (0) 0 (0) 3 (14) 8 (32) 2 (3)
Portal venopathy 1 (2) 0 (0) 0 (0) 4 (17) 0 (0)
Copper 0.10 0.12 0.09 0.74 0.13
Patterns of DILI with particular agents
(only one agent implicated)
Amoxicillin/clavulanate 0 0 3 3 9
Nitrofurantoin 2 4 0 2 1
Minocycline 3 2 0 0 2
Sulfamethoxazole/trimethoprim 1 0 1 0 4
Data are shown as N (%) or as mean values. Means of scores are shown only for simplicity.
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were found more frequently in those with severe or
fatal injury, consistent with the previous study. Simi-
larly, a large meta-analysis of case reports of DILI
demonstrated that necrosis was associated with poor
outcome, whereas eosinophils were associated with a
good outcome.17 Both observations were confirmed in
our prospective, blinded study. In addition to these
findings, we observed that fibrosis, microvesicular stea-
tosis, cholangiolar cholestasis, neutrophils, and portal
venopathy were associated with either severe or fatal
Table 5. Significant Associations of Histological Findings With Outcome
Severe or Fatal Fatal Outcome
Feature No Yes P Value* No Yes P Value*
Total N 162 46 193 15
Granulomas
None 57 (35) 28 (62) 0.0010 74 (39) 11 (73) 0.0300
Microgranulomas 97 (60) 13 (29) 106 (55) 4 (27)
Epith granulomas 8 (5) 4 (9) 12 (6) 0 (0)
Eosinophils 76 (47) 10 (22) 0.0030 84 (44) 2 (13) 0.0300
Neutrophils 43 (27) 22 (49) 0.0060
Degree of necrosis, mean 0.36 0.89 0.0100 0.43 1.13 0.0200
Fibrosis stage, mean 1.15 1.73 0.0030 1.18 2.53 <0.0001
Type of steatosis
Macrovesicular 84 (82) 12 (39) <0.0001 95 (77) 1 (9) <0.0001
Mixed 9 (9) 10 (32) 14 (11) 5 (46)
Microvesicular 10 (10) 9 (29) 14 (11) 5 (46)
Cholangiolar cholestasis 2 (1) 6 (13) 0.0020 5 (3) 3 (20) 0.0100
Ductular reaction 52 (32) 24 (53) 0.0100 65 (34) 15 (73) 0.0040
Portal venopathy 4 (2) 2 (17) 0.0400
Data are shown as either mean score or N (%). Means of scores are shown only for simplicity.
*Statistical significance of differences was evaluated using chi-square test or Fisher’s exact test for 2 3 2 comparisons.
Fig. 3. Histological features associated with outcome. (A) Zone 3 coagulative necrosis in a patient with severe injury resulting from duloxetine.
(B) Microvesicular steatosis in a patient with fatal injury probably resulting from erythromycin. (C) Ductular reaction, cholangiolar cholestasis,
and neutrophilic infiltration in a patient with severe injury resulting from duloxetine. (D) Granulomatous and eosinophilic inflammation in a
patient with moderate (but hospitalized) injury probably resulting from atenolol.
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injury, whereas granulomas were associated with mild
or moderate injury. There may be multiple explana-
tions for these findings, some of which may be related
to true drug injury, whereas others may be related to
underlying liver disease or other comorbidities.
Advanced fibrosis can be caused by drugs such as ami-
odarone18 and nitrofurantoin19,20 or may be the result
of an underlying chronic liver disease. In either case,
advanced fibrosis may limit the ability of the liver to
respond to acute injury. Only one case was diagnosed
with the overall pattern of microvesicular steatosis,
whereas 27% showed either microvesicular steatosis
alone or in combination with macrovesicular steatosis
as part of another histological injury pattern. Microve-
sicular steatosis has often been related to mitochondrial
injury, and it is possible that this mechanism may be
occurring alongside other mechanisms of liver injury
in DILI.21 Cholangiolar cholestasis is a characteristic
finding in sepsis and may be acting as a marker of this
comorbidity. Neutrophils are commonly observed asso-
ciated with ductular reaction and cholangiolar choles-
tasis and therefore may not be an independent marker
of poor outcome. Granulomas, both large epithelioid
granulomas and microgranulomas, were a common
finding, noted in 62% of cases. Eosinophils and granu-
lomas were the only findings that were inversely associ-
ated with severe injury. Both are thought be
histological evidence of immunoallergic reactions that
generally carry a better prognosis than other kinds of
DILI.17 The diversity of findings associated with clini-
cal severity suggests that multiple mechanisms may be
responsible for the severity of injury in any particular
case.
There were a number of strengths and limitations to
this study. This systematic histological assessment of a
large number of liver biopsies in patients with detailed
clinical and laboratory data represented a unique
opportunity to combine these facets in well-
characterized DILIN study patients. Despite the
diverse nature of the patient population and the large
number of agents implicated, a number of common
observations could be made based on these data: Liver
histology can be categorized according to stereotypical
patterns of injury, and these patterns of injury, though
generally correlated with biochemical patterns, do not
match perfectly. Histological evaluation allows the dis-
tinction of different tissue injury patterns that may all
present with similar biochemical patterns. Finally, there
are a variety of histological changes and patterns of
injury that are associated with clinical severity and,
indirectly, with outcome. The histological review for
DILIN was done by a single pathologist, which repre-
sents both a strength and a limitation. For DILIN, it
permitted a fresh, internally consistent reexamination
of the histological findings. However, it precluded a
consensus approach to biopsy evaluation or an interob-
server validation study. Nevertheless, our standardized
approach used patterns and individual histological fea-
tures that are well described in textbooks of hepatic
pathology, so these methods should be readily accessi-
ble to experienced hepatic pathologists. In addition,
the study was limited, in that biopsies were done only
when considered clinically indicated and were not per-
formed in all patients enrolled in DILIN. The liver
biopsy is one of several diagnostic tools available and
was not considered clinically necessary for all cases,
and the criteria used to perform a biopsy may have
varied among the eight enrolling centers. It is not pos-
sible to know how biases in biopsy collection might
have affected the data, but it is likely that the inci-
dence of certain histological patterns of injury might
be different if every patient had undergone liver
biopsy. However, it is unlikely that these biases would
affect the correlations observed between the biopsies
and the corresponding clinical data.
This study was not designed to address the diagnos-
tic utility of liver biopsy in DILI. Although biopsy
may be a useful diagnostic and management tool in
DILI, we are unable to delineate specific advantages in
the context of the current DILIN study. This study
was also not designed to address whether there are par-
ticular biopsy features that should suggest DILI, as
opposed to other diagnoses, although we did observe a
few differences in biopsies later confirmed to be DILI.
However, to demonstrate differences in DILI cases,
additional control cases with similar clinical presenta-
tions and/or patterns of injury would need to be
matched to authentic cases of DILI, as was done in
the recent comparison of autoimmune hepatitis cases
to DILI.22
The liver biopsy remains a valuable tool in the eval-
uation of patients suspected to have DILI. As a clinical
test, it provides more information about the state of
the liver than any other single assay. Pathologists
should make use of the full spectrum of hepatic injury
patterns when assessing and reporting on DILI,6 either
in practice or in publications. Analysis of the pattern
of injury provides a pathological differential diagnosis
that can be evaluated against the clinical differential
diagnosis and matched to published patterns of injury
caused by suspect agents. The pattern classification
should be accompanied by a detailed description of
the severity and distribution of individual pathological
findings. Histological observations can provide a direct,
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unambiguous assessment of the severity of liver injury
that can help guide clinical management. Our study
provides extensive data on the relationship between
histological and clinical observations and provides a
standardized framework for systematic review and clas-
sification of pathological changes in liver biopsies.
Adoption of a standardized, systematic approach to
describe the histology of DILI will allow for compari-
son of findings across studies and will help in stand-
ardizing management and providing insights into
pathogenesis as well as approaches to therapy.
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